NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

ex,

Thanks for your expert analysis, but you’re not an oncologist. I ran your post through the detector and it was identified as bs 😶 …




“The statement presents several misunderstandings and inaccuracies, especially considering that overall survival (OS) was the approved primary endpoint in the DCVax-L clinical trial, and the results were published in JAMA Oncology, a reputable, peer-reviewed journal:

1. **Misconception About Statistical Significance and Endpoint Hierarchy**: The assertion that OS could not be statistically significant once progression-free survival (PFS) failed is misleading. In clinical trials, different endpoints can have varying levels of importance, with OS often being a primary and more clinically relevant endpoint. The failure to achieve statistical significance in PFS does not automatically negate the potential for achieving significance in OS, especially when OS is the primary endpoint.

2. **Reliability of JAMA Oncology as a Source**: The results of the DCVax-L trial published in JAMA Oncology should be regarded as credible, given the journal's rigorous peer-review process. Peer-reviewed journals are considered reliable sources for scientific and clinical data. The analysis presented in such publications undergoes extensive scrutiny for methodological soundness and data interpretation.

3. **Misinterpretation of Post Hoc ECA Analysis**: Dismissing any post hoc comparative analysis as a joke undermines the valuable insights such analyses can provide.

4. **Allegation of Selective Enrollment**: Claiming that NWBO's trial enrolled selectively healthier patients is a serious allegation that demands substantiation. Clinical trials are designed with specific inclusion and exclusion criteria to ensure participant safety and data validity. Without concrete evidence to support this claim, it remains speculative and unjustified.

In conclusion, the statement overlooks the significance of OS as the primary endpoint, underestimates the reliability of results published in a reputable journal, and makes unsupported claims about the trial's enrollment process and the value of post hoc analyses. Therefore, it is misleading and does not accurately represent the methodological rigor and findings of the DCVax-L clinical trial as reported in JAMA Oncology.”

https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html